» Articles » PMID: 28685051

Personalized Medicine Could Transform Healthcare

Overview
Journal Biomed Rep
Specialty Biochemistry
Date 2017 Jul 8
PMID 28685051
Citations 99
Authors
Affiliations
Soon will be listed here.
Abstract

Personalized medicine (PM) is about tailoring a treatment as individualized as the disease. The approach relies on identifying genetic, epigenomic, and clinical information that allows the breakthroughs in our understanding of how a person's unique genomic portfolio makes them vulnerable to certain diseases. PM approach is a complete extension of traditional approach (One-Size-Fits-All) to increasing our ability to predict which medical treatments will be safe and effective for individual patient, and which ones will not be, based on the patient's unique genetic profile. Implementation of PM has the potential to reduce financial and time expenditure, and increase quality of life and life extension of patients. Knowledge of PM facilitates earlier disease detection via enhanced use of existing biomarkers and detection of early genomic and epigenomic events in disease development, particularly carcinogenesis. The PM approach predominantly focuses on preventative medicine and favours taking pro-active actions rather than just reactive. This approach delays or prevents the need to apply more severe treatments which are usually less tolerated and with increased quality of life and financial considerations. Increasing healthcare costs have placed additional pressure on government funded healthcare systems globally, especially regarding end of life care. PM may increase the effectiveness of existing treatments and negate the inherent problems associated with non-PM approaches. PM is a young but rapidly expanding field of healthcare where a physician can select a treatment based on a patient's genetic profile that may not only minimize harmful side effects and guarantee a more successful result, but can be less cost effective compared with a 'trial-and-error' approach to disease treatment. The less efficient non-PM ('trial-and-error') approach, which can lead to drug toxicity, severe side effects, reactive treatment and misdiagnosis continue to contribute to increasing healthcare costs. Increased patient stratification will allow for the enhanced application of PM and pro-active treatment regimens, resulting in reduced costs and quality of life enhancement.

Citing Articles

Digital Health Technologies in Pediatric Infectious Disease and the Perspective of Patients and Healthcare Professionals: A Review.

Saji A, Komel A, Khan M, Niraula S, Naeem B, Ahsan A Health Sci Rep. 2025; 8(3):e70514.

PMID: 40041773 PMC: 11872690. DOI: 10.1002/hsr2.70514.


L-Arginine and Nitric Oxide in Vascular Regulation-Experimental Findings in the Context of Blood Donation.

Kurhaluk N, Tkaczenko H Nutrients. 2025; 17(4).

PMID: 40004994 PMC: 11858268. DOI: 10.3390/nu17040665.


Integrating Analytical Procedures in Routine Practices of Centralized Antiblastic Compounding Units for Valorization of Residual Compounded Drugs.

Aquino R, Falcone G, Russo P, Dal Piaz F, Auriemma G, de Francesco F Pharmaceutics. 2025; 17(1).

PMID: 39861749 PMC: 11769000. DOI: 10.3390/pharmaceutics17010101.


Transcriptional Systems Vaccinology Approaches for Vaccine Adjuvant Profiling.

Pellegrina D, Wilson H, Mutwiri G, Helmy M Vaccines (Basel). 2025; 13(1.

PMID: 39852812 PMC: 11768747. DOI: 10.3390/vaccines13010033.


Emerging Strategies for Revascularization: Use of Cell-Derived Extracellular Vesicles and Artificial Nanovesicles in Critical Limb Ischemia.

Ravi Mythili V, Rajendran R, Arun R, Loganathbabu V, Reyaz D, Nagarajan A Bioengineering (Basel). 2025; 12(1).

PMID: 39851366 PMC: 11762151. DOI: 10.3390/bioengineering12010092.


References
1.
Hood L, Galas D . The digital code of DNA. Nature. 2003; 421(6921):444-8. DOI: 10.1038/nature01410. View

2.
Sadee W, Dai Z . Pharmacogenetics/genomics and personalized medicine. Hum Mol Genet. 2005; 14 Spec No. 2:R207-14. DOI: 10.1093/hmg/ddi261. View

3.
Khoury M, Gwinn M, Yoon P, Dowling N, Moore C, Bradley L . The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention?. Genet Med. 2007; 9(10):665-74. DOI: 10.1097/GIM.0b013e31815699d0. View

4.
Hamburg M, Collins F . The path to personalized medicine. N Engl J Med. 2010; 363(4):301-4. DOI: 10.1056/NEJMp1006304. View

5.
Vogenberg F, Barash C, Pursel M . Personalized medicine: part 1: evolution and development into theranostics. P T. 2010; 35(10):560-76. PMC: 2957753. View